While immune checkpoint blockade has revolutionized the treatment of multiple cancers, only a subset of patients initially respond and many relapse with acquired resistance to this treatment. Using a combination of modeling and antibody engineering strategies, this project aims to explore the mechanisms of the PD-1/PD-L1 checkpoint axis to improve the therapeutic efficacy when drugging these targets.
|K. Dane Wittrup, Ph.D.
C. P. Dubbs Professor of Chemical Engineering and Bioengineering
Associate Director, Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
500 Main Street,
Cambridge, MA 02139
Office Phone: 617-253-4578
Department of Chemical Engineering
Department of Biological Engineering
Koch Institute for Integrative Cancer Research